In melanoma, tumor PD-L1 expression showed a significant correlation with response to five out of eight iCPI studies treating patients with anti-PD-1 mAb, while it did not predict response to anti-CTLA-4 therapy (94). This evidence concerns the gene PDCD1 and melanoma.